Premium
8‐Methoxypsoralen Serum Levels in Poor Responders to Photochemotherapy
Author(s) -
Walther Thomas,
Haustein UweFrithjof
Publication year - 1991
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4362.1991.tb04877.x
Subject(s) - methoxsalen , medicine , puva therapy , psoriasis , psoralen , dermatology , gastroenterology , pharmacology , biochemistry , dna , chemistry
8‐Methoxypsoralen (8‐MOP) serum levels of psoriatic patients poorly responsive to photochemotherapy (PUVA) treatment (problem cases) were determined by the HPLC method with 11 single blood probes over 8 hours. Abnormally low or deviated serum levels were found in 7 of 11 PUVA problem patients. There was a great interindividually different first‐pass effect for 8‐MOP in dependence on the galenic formulation of the 8‐MOP brand; therefore, the change to another 8‐MOP brand with a modern galenic formulation led only to a slight increase of serum levels, and consequently an increase in the 8‐MOP dosage was necessary. It is important to be cautious at this point because patients may show an unproportional increase of 8‐MOP serum levels due to the individually limited capacity of biotransformation. The studies of the authors reaffirm the necessity of the determination of 8‐MOP serum levels in problem cases of PUVA therapy.